key: cord-0905976-xu91dth0 authors: Menga, Luca S.; Berardi, Cecilia; Ruggiero, Ersilia; Grieco, Domenico Luca; Antonelli, Massimo title: Noninvasive respiratory support for acute respiratory failure due to COVID-19 date: 2021-10-21 journal: Curr Opin Crit Care DOI: 10.1097/mcc.0000000000000902 sha: e94c05fa9521907ea6dda1d13a72f3c1e7a845cf doc_id: 905976 cord_uid: xu91dth0 Noninvasive respiratory support has been widely applied during the COVID-19 pandemic. We provide a narrative review on the benefits and possible harms of noninvasive respiratory support for COVID-19 respiratory failure. RECENT FINDINGS: Maintenance of spontaneous breathing by means of noninvasive respiratory support in hypoxemic patients with vigorous spontaneous effort carries the risk of patient self-induced lung injury: the benefit of averting intubation in successful patients should be balanced with the harms of a worse outcome in patients who are intubated after failing a trial of noninvasive support. The risk of noninvasive treatment failure is greater in patients with the most severe oxygenation impairment (PaO(2)/FiO(2) < 200 mmHg). High-flow nasal oxygen (HFNO) is the most widely applied intervention in COVID-19 patients with hypoxemic respiratory failure. Also, noninvasive ventilation (NIV) and continuous positive airway pressure delivered with different interfaces have been used with variable success rates. A single randomized trial showed lower need for intubation in patients receiving helmet NIV with specific settings, compared to HFNO alone. Prone positioning is recommended for moderate-to-severe acute respiratory distress syndrome patients on invasive ventilation. Awake prone position has been frequently applied in COVID-19 patients: one randomized trial showed improved oxygenation and lower intubation rate in patients receiving 6-h sessions of awake prone positioning, as compared to conventional management. SUMMARY: Noninvasive respiratory support and awake prone position are tools possibly capable of averting endotracheal intubation in COVID-19 patients; carefully monitoring during any treatment is warranted to avoid delays in endotracheal intubation, especially in patients with PaO(2)/FiO(2) < 200 mmHg. The optimal management of hypoxemic respiratory failure is debated. Most recent guidelines suggest caution in using noninvasive respiratory support -namely high-flow nasal oxygen (HFNO), noninvasive ventilation (NIV) or continuous positive endexpiratory pressure (CPAP) -for the early treatment of hypoxemic respiratory failure due to COVID-19 [1] and non-COVID-19 etiology [2] . Early endotracheal intubation has been advocated in the early phases of the pandemic to limit the risks related to prolonged exposure of injured lungs to the potential harms of intense inspiratory efforts and high tidal volumes [3] . However, intubation with invasive mechanical ventilation can lead to serious complications, including ventilator-induced lung injury, intensive care unit (ICU)-acquired pneumonia, diaphragmatic atrophy and ICU-induced delirium, with detrimental effects on clinical outcome [4, 5] . During the COVID-19 pandemic, the unprecedented lack of mechanical ventilators and ICU beds led clinicians to extensively use noninvasive respiratory support for the treatment of hypoxemic respiratory failure [6] [7] [8] [9] . Patients with hypoxemic respiratory failure often show dysregulated respiratory drive. The harmful effects of spontaneous breathing with intense inspiratory effort can result in self-induced lung injury (P-SILI). P-SILI may worsen the clinical outcome of patients who require endotracheal intubation after having received noninvasive respiratory support [10, 11] . As the debate remains open, we searched MED-LINE-PubMed databases for the relevant articles (up to August 2021) assessing the physiological and clinical effects of noninvasive respiratory support in patients with acute respiratory failure of COVID-19 etiology. In this review, we provide an overview of the available evidence regarding the use of noninvasive respiratory support in COVID-19 patients, highlighting its benefits and potential risks. In hypoxemic respiratory failure, lung injury yields altered respiratory mechanics and increased dead space; inflammation combined to biochemical stimuli induced by hypoxemia, respiratory acidosis with hypercarbia, and the 'chemomechanical' variations due to atelectasis and alveolar derecruitment increase patient's ventilatory demand. This results in a shift of brain homeostasis toward a lower level of PaCO 2 , which can cause spontaneous ventilation with high inspiratory effort, large tidal volumes and tachypnea, leading to abnormal inspiratory swings of pleural pressure and consequent increment of the transpulmonary pressure (alveolar pressure -esophageal pressure as a surrogate of the pleural pressure). As a consequence, baro-, volu-and atelec-trauma are generated. These mechanisms lead to the progression of lung injury [12 & ,13 & , [14] [15] [16] [17] [18] . Additionally, the increase in transmural pressure of lung vessels combined with their increased permeability concur to alveolar flooding and negative pressure pulmonary edema [15, 19] . Under this scenario, the damaged lung can exhibit two distinct patterns: the healthy lung has a more fluid-like condition in the nondependent regions, whereas the most damaged and atelectatic regions have a solid-like pattern (the dependent regions). The solid-like regions transmit pleural pressure differently from the fluid-like regions, finally generating intra-tidal heterogeneity of transpulmonary pressure. This causes an intra-tidal shift of gas from nondependent regions of the lung to the dependent regions; this occult movement of air is called 'pendelluft', and can overstretch dependent lung regions independently from the size of inspired volume, increasing inflammation and regional strain [20] . Delivering high positive end-expiratory pressure (PEEP) during spontaneous breathing might render spontaneous effort noninjurious through different mechanisms: (1) it increases functional residual capacity, reducing the extension of atelectatic regions, finally decreasing the mechanical stimuli yielding the increase of respiratory drive, (2) it yields diaphragmatic uncoupling, reducing the inspiratory effort, (3) it limits the occurrence of pendelluft phenomenon by favoring a more homogeneous transmission of the pleural pressure across the lung tissue [12 & ,21,22] . Although these considerations may advocate against the use of noninvasive respiratory support, it appears that patients with hypoxemic respiratory failure due to COVID-19 exhibit average lower inspiratory effort than non-COVID-19 patients with similar oxygenation impairment, possibly indicating a reduced risk of P-SILI [23] . Available data indicate that, in patients with PaO 2 /FiO 2 > 200mmHg, noninvasive respiratory support is safe and effective. Differently, in patients with PaO 2 /FiO 2 200 mmHg, the best balance between the benefits and harms of maintaining spontaneous breathing with noninvasive respiratory support has yet to be identified [8, 24] . When considering a noninvasive respiratory support trial, the optimal strategy should aim to limit the risk of endotracheal intubation, without increasing the risk of P-SILI: [25] this is of particular importance given the high failure rate of noninvasive respiratory support in COVID-19 hypoxemic respiratory failure when compared to non-COVID-19 patients [26 & ]. HFNO is a technique that delivers high flow rates (60 L/min) of humidified and heated oxygen at adjustable FiO 2 through nasal cannula. HFNO allows (1) accurate delivery of the set FiO 2 by limiting dilution of inhaled gas, (2) provides carbon dioxide washout of the upper airways and reduction of physiological dead space when the flow rates is > 30 L/min (3) and variable PEEP that increases with flow rates, ultimately reducing inspiratory effort [27, 28] . A randomized trial showed that HFNO might reduce intubation rate and mortality in moderateto-severe hypoxemic respiratory failure when compared to low flow oxygen and face mask NIV [24] , and the latest guidelines [2, 29] suggest HFNO as the optimal first line intervention to correct hypoxemia during de novo respiratory failure. Despite the initial concerns about the risk of viral aerosolization and transmission to healthcare workers -that can be mitigated by a surgical mask on top of high-flow nasal cannula, which also improves oxygenation [30] -HFNO has been widely applied in patients with acute respiratory failure due to COVID-19 in heterogeneous clinical scenarios, with highly variable outcomes in terms of endotracheal intubation and mortality rate [31] [32] [33] [34] [35] [36] [37] ( Table 1) . In ICU and non-ICU settings, patients with COVID-19 and PaO 2 /FiO 2 ratio < 300 mmHg have been treated with HFNO, showing rates of endotracheal intubation and mortality rate as low as 0% in very mild patients [38] up to a failure rate as high as 80% in the most severe ones [39,40 && ] (Fig. 1a) . Indeed, during the COVID-19 pandemic, HFNO has shown a great efficacy in patients with a PaO 2 / FiO 2 ratio > 200 mmHg [38, 41] , whereas it may be associated to higher risk of failure when PaO 2 / FiO 2 < 200 mmHg [42] [43] [44] [45] . Overall, available data indicate that HFNO in COVID-19 patients with acute respiratory failure do not increase mortality rate and may be an effective strategy in mild-to-moderate cases to reduce the need for mechanical ventilation and critical care support [46, 47] . As any other form of noninvasive respiratory support, HFNO should be applied under strict clinical monitoring to promptly detect treatment failure and reduce the risks related to delayed endotracheal intubation, P-SILI and poor prognosis. The ROX index, which is the SpO 2 normalized to FiO 2 times respiratory rate has been validated in the non-COVID setting [48] , has been examined by several authors to be adapted to COVID-19 patients. Preliminary data show that ROX index in COVID-19 patients could be a simple marker to predict the risk of HFNO failure and could be used to prevent the delay in endotracheal intubation: however, different thresholds have been suggested, ranging from 3.67 to 5.37, and the optimal cut-off for COVID-19 patients remains to be clarified [42] [43] [44] 47, 49] . NIV has progressively been identified in the last 20 years as valid treatment in the management of acute respiratory failure. Specific indications are exacerbation of chronic obstructive pulmonary disease, cardiogenic pulmonary edema, pneumonia in immunocompromised patients and weaning of previously intubated stable patients with chronic obstructive pulmonary disease. Conversely, in the treatment of hypoxemic respiratory failure, NIV use has been associated with conflicting results, and the most recent guidelines suggest caution in its application [2, 29] . Clinical outcome improves when NIV allows to avoid endotracheal intubation. Differently, if intubation is needed after NIV, mortality is increased, possibly due to delayed intubation and the prolonged exposure of injured lungs to P-SILI [50] . In the recent years, various interfaces have been used, as face (or oro-nasal/full-face) mask, nasal masks, mouthpieces, nasal pillows or plugs, and helmet; each has its own peculiarities and pitfalls, that must be part of the clinician's evaluation. NIV improves oxygenation, reduces dyspnea, inspiratory effort and work of breathing [51] , and might reduce the rate of endotracheal intubation and ICU mortality rate [52 tolerability, allowing the patient to receive continuous treatments with enhanced comfort [55] ; this is particularly important in the early phases of hypoxemic respiratory failure, when high PEEP seems a promising tool to mitigate the risk of P-SILI [21, 56, 57] . In 2016, a randomized study showed lower intubation rate and improved outcome in hypoxemic patients treated with helmet NIV vs those treated with face-mask NIV; whereas patients with helmet received a median sustained PEEP of 8 cmH 2 O, patients treated with face mask received a median PEEP of 5.1 cmH 2 O [58] . During the COVID-19 pandemic, NIV has been used both as a first-line therapy and as rescue therapy after HFNO, in patients with wide range of severity [59] [60] [61] [62] [63] [64] [65] (Table 2 ). NIV showed variable success rates during the pandemic, possible due to the heterogeneous interfaces, settings and protocols applied; Wang et al. report a failure rate of 11% in mild-to-moderate patients when NIV is used as first-line therapy (Fig. 1b) . Lastly, a randomized controlled trial compared the efficacy of continuous helmet NIV vs HFNO alone in COVID-19 patients affected by moderateto-severe hypoxemia. In this study, despite the lack of a significant difference on the primary outcome (median days free of respiratory support at 28 ]. NIV can be a powerful instrument as optimal settings and adequate interface are provided, but careful selection and strict clinical monitoring of patients are mandatory to reduce the risk of delayed intubation. The use of CPAP in hypoxemic respiratory failure has been proposed more than 20 years ago, but a randomized controlled trial failed to prove its efficacy in reducing the intubation rate in patients with hypoxemic respiratory failure of other etiologies [71] . Nevertheless, in the subsequent years, Helmet CPAP has become increasingly used to increase blood oxygenation and reduce the risk of intubation in patients with moderate-to-severe hypoxemia compared with standard oxygen [72, 73] . Traditionally CPAP is provided with a device able to provide high flow rates of fresh gas flow (inlet port) and an adjustable PEEP valve (outlet port), being highly cost-effective in the emergency context and easily used outside the ICU. CPAP has been adopted to increase blood oxygenation and to avoid endotracheal intubation and as ceiling of treatment in patients with limitation of care: in patients who were not candidate for receiving invasive mechanical ventilation, CPAP has been used as a rescue therapy, with mortality ranging from 0% to 90% [ . When compared to other noninvasive respiratory support strategies or to standard oxygen, early case-series showed a trend to a reduction in the intubation rate in patients treated with CPAP [86, 87] , but the largest observational trial to date [67 && ] showed no difference in intubation and mortality rates (Fig. 1c) . Nevertheless, CPAP is a powerful instrument that can be safely used outside of the ICU, with good success in the less severe patients, especially when the Helmet interface is used. However, the increase in the PaO 2 /FiO 2 ratio induced by PEEP might generate a false sense of security, possibly causing delays in the decision to intubate the patient: the clinician should pay close attention to the change of physiological variables over time [77, 88] and, when available, should consider evaluating diaphragm thickening fraction [89, 90] and lung ultrasound [91] to enhance early detection of treatment failure. In moderate-to-severe acute respiratory distress syndrome patients receiving invasive mechanical ventilation, prone positioning improves oxygenation, reduces ventilator-induced lung injury, finally reducing mortality [92 && ,93,94 && ]. In the midst of the pandemic, awake prone positioning was initially used on the most severe patients that required noninvasive respiratory support as a rescue strategy to avoid intubation, both in the ICU and in the non-ICU setting. Prone positioning in spontaneously breathing patients improves oxygenation and lowers inspiratory effort [94 && ] and respiratory rate, but the improvement is often transient, and only a minority of patients show sustained benefit after resupination (Table 4) . Several pilot studies have investigated whether it could improve patient-centered outcomes, but results are conflicting (Fig. 1d) . The largest retrospective, multicenter, observational study showed a reduction in the intubation rate in patients who received awake prone position for at least 2 consecutive hours, compared to patients who did not receive this intervention [124 && ]. Three small, randomized feasibility trials available showed no benefit on endotracheal intubation rate and on mortality [125, 126, 127 & ]. In the trial designed by Rosén et al. 0% [95% CI 0 to 28] PP is potentially a low-cost, easily implemented, and scalable intervention, particularly in low-and middle-income countries. After 1h of PP SpO2 improved to 98% [97] [98] [99] and respiratory rate was reduced to 22 [18] [19] [20] [21] [22] [23] [24] [25] from 31 [28] [29] [30] [31] [32] [33] [34] [35] [36] [37] [38] [39] . Acute respiratory failure due to COVID-19 Menga et al. Not reported Awake PP could improve blood oxygenation and potentially avoid endotracheal intubation. Mean PaO2 increased from 69 (10) to 108 (14) with awake PP (P < 0.00) and PaCO2 decreased from 47 (7) to 39 (5) respectively), resolved in no difference in intubation rate, and the trial was stopped early for futility. Lately, a prospective, randomized, collaborative meta-trial compared awake prone position and conventional in patients treated with HFNO with acute respiratory failure of COVID-19 etiology. The authors found a reduction in the proportion of patients intubated or dying within 28 days from enrolment (40% in the awake prone position group vs 46% in the standard of care group, P ¼ 0.007) [128 && ]. Interestingly, average duration of prone positioning sessions was 6 h, and longer sessions were associated with treatment success at 28 days: this finding should be interpreted as exploratory. Awake prone position appears as a cost-effective technique that can improve the blood oxygenation and reduce the respiratory rate [129] , and a recent randomized controlled trial support its routine use in patients with respiratory failure of COVID-19 etiology treated with HFNO [128 && ]. Currently, noninvasive respiratory support is a safe option in patients with a PaO 2 /FiO 2 ! 200 mmHg; in patients PaO 2 /FiO 2 < 200 mmHg most recent randomized controlled trials suggest HFNO or helmet NIV as the most promising techniques for a noninvasive respiratory support trial [24, 51, 56] . In the COVID-19 pandemic, awake prone position, which has a robust physiological rationale, has been widely applied with benefits on oxygenation and a possible reduction in the rate of endotracheal intubation [87] . During any treatment, careful clinical monitoring remains mandatory not to delay the intubation and protective ventilation, especially in patients with PaO 2 /FiO 2 < 200 mmHg. Values are displayed as means (SD) or medians [Interquartile range]. Failure was defined as either intubation, death while still on noninvasive respiratory support, or escalation to other noninvasive respiratory support to avoid endotracheal intubation. AHRF, acute hypoxemic respiratory failure; ARDS, acute respiratory distress syndrome; awake PP, awake prone position; CPAP, continuous positive end-expiratory pressure; FiO 2 , fraction of inspired oxygen; HFNO, high-flow nasal oxygen; ICU, intensive care unit; IQR, interquartile range; NIV, noninvasive ventilation; PaO 2 , partial pressure of arterial oxygen; PEEP, positive end-expiratory pressure; SAPS, Simplified Acute Physiology Score; SOFA, Sequential Organ Failure Assessment; SpO 2 , peripheral capillary oxygen saturation; VFD, Ventilatory Free Days. Clinical management Clinical management Living guidance COVID-19 Official ERS/ATS clinical practice guidelines: noninvasive ventilation for acute respiratory failure COVID-19 pneumonia: different respiratory treatments for different phenotypes? Caution about early intubation and mechanical ventilation in COVID-19 Ventilation management and clinical outcomes in invasively ventilated patients with COVID-19 (PRoVENT-COV-ID): a national, multicentre, observational cohort study Early consensus management for non-ICU acute respiratory failure SARS-CoV-2 emergency in Italy: from ward to trenches Noninvasive ventilation and high-flow oxygen therapy for severe community-acquired pneumonia Noninvasive ventilatory support and high-flow nasal oxygen as first-line treatment of acute hypoxemic respiratory failure and ARDS Mechanical-ventilation supply and options for the COVID-19 Pandemic. Leveraging all available resources for a limited resource in a crisis Patient self-inflicted lung injury: implications for acute hypoxemic respiratory failure and ARDS patients on noninvasive support Noninvasive respiratory support and patient self-inflicted lung injury in COVID-19: a narrative review Respiratory drive in the acute respiratory distress syndrome: pathophysiology, monitoring, and therapeutic interventions Interesting review summarizing the patophysiology of respiratory drive in acute hypoxemic respiratory failure Respiratory drive in critically ill patients pathophysiology and clinical implications Interesting review summarizing the patophysiology of respiratory drive in acute hypoxemic respiratory failure Dyspnoea in patients receiving noninvasive ventilation for acute respiratory failure: prevalence, risk factors and prognostic impact Lung opening and closing during ventilation of acute respiratory distress syndrome Mechanical ventilation to minimize progression of lung injury in acute respiratory failure Spontaneous breathing during lung-protective ventilation in an experimental acute lung injury model: high transpulmonary pressure associated with strong spontaneous breathing effort may worsen lung injury Dyspnea and clinical outcome in critically ill patients receiving noninvasive support for COVID-19 respiratory failure: posthoc analysis of a randomized clinical trial Negative-pressure pulmonary edema Spontaneous effort causes occult pendelluft during mechanical ventilation High positive end-expiratory pressure renders spontaneous effort noninjurious Spontaneous effort during mechanical ventilation: maximal injury with less positive end-expiratory pressure Inspiratory effort and lung mechanics in spontaneously breathing patients with acute respiratory failure due to COV-ID-19: a matched control study High-flow oxygen through nasal cannula in acute hypoxemic respiratory failure Lung and diaphragm-protective ventilation Prospective observational study showing that COVID-19 patients treated with noninvasive respiratory support have higher risk of failure than matched patients with respiratory failure of other etiology Physiologic effects of high-flow nasal cannula in acute hypoxemic respiratory failure Nasal high flow higher than 60 L/min in patients with acute hypoxemic respiratory failure: a physiological study Surviving Sepsis Campaign: guidelines on the management of critically ill adults with Coronavirus Disease 2019 (COVID-19) Surgical mask on top of high-flow nasal cannula improves oxygenation in critically ill COVID-19 patients with hypoxemic respiratory failure. Ann Intensive Care 2020 High-flow nasal cannula in critically Ill patients with severe COVID-19 Timing of intubation and mortality among critically ill coronavirus disease 2019 patients: a single-center cohort study High-flow nasal oxygen in patients with COVID-19-associated acute respiratory failure COVID-19 pneumonia and ROX index: time to set a new threshold for patients admitted outside the ICU High-flow nasal cannula oxygen therapy to treat patients with hypoxemic acute respiratory failure consequent to SARS-CoV-2 infection Implications of early respiratory support strategies on disease progression in critical COVID-19: a matched subanalysis of the prospective RISC-19-ICU cohort Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study High flow nasal cannula is a good treatment option for COVID-19 Clinical course and outcomes of 344 intensive care patients with COVID-19 A simple nomogram for predicting failure of noninvasive respiratory strategies in adults with COVID-19: a retrospective multicentre study Well designed study that provides the reader a nomogram and an online calculator to predict the risk of noninvasive respiratory support failure in COVID-19 patients The experience of high-flow nasal cannula in hospitalized patients with 2019 novel coronavirus-infected pneumonia in two hospitals of Chongqing Prediction of outcome of nasal high flow use during COVID-19-related acute hypoxemic respiratory failure Validity of ROX index in prediction of risk of intubation in patients with COVID-19 pneumonia High-flow nasal cannula for acute respiratory distress syndrome (ARDS) due to COVID-19 Ventilatory ratio in hypercapnic mechanically ventilated patients with COVID-19-associated acute respiratory distress syndrome High-flow nasal oxygen in coronavirus disease 2019 patients with acute hypoxemic respiratory failure: a multicenter, retrospective cohort study High flow nasal oxygen therapy to avoid invasive mechanical ventilation in SARS-CoV-2 pneumonia: a retrospective study An index combining respiratory rate and oxygenation to predict outcome of nasal high flow therapy High-flow nasal cannula therapy in COVID-19: using the ROX index to predict success Noninvasive ventilation of patients with acute respiratory distress syndrome. Insights from the LUNG SAFE Study Physiological comparison of high-flow nasal cannula and helmet noninvasive ventilation in acute hypoxemic respiratory failure Association of noninvasive oxygenation strategies with all-cause mortality in adults with acute hypoxemic respiratory failure: a systematic review and meta-analysis Systematic review and meta-analysis summarizing the potential harms and benefits of noninvasive respiratory support in patients affected by acute hypoxemic respiratory failure Effectiveness of mask and helmet interfaces to deliver noninvasive ventilation in a human model of resistive breathing Helmet with specific settings versus facemask for noninvasive ventilation New treatment of acute hypoxemic respiratory failure: noninvasive pressure support ventilation delivered by helmet-a pilot controlled trial Patient-ventilator interaction in ARDS patients with extremely low compliance undergoing ECMO: a novel approach based on diaphragm electrical activity Fifty years of research in ARDS. Spontaneous breathing during mechanical ventilation. risks, mechanisms, and management Effect of noninvasive ventilation delivered by helmet vs face mask on the rate of endotracheal intubation in patients with acute respiratory distress syndrome Noninvasive ventilation for SARS-CoV-2 acute respiratory failure: a subanalysis from the HOPE COVID-19 registry Severity of respiratory failure and outcome of patients needing a ventilatory support in the Emergency Department during Italian novel coronavirus SARS-CoV2 outbreak: Preliminary data on the role of Helmet CPAP and Non-Invasive Positive Pressure Ventilati Effectiveness and safety of noninvasive positive pressure ventilation in the treatment of COVID-19-associated acute hypoxemic respiratory failure: a single center, non-ICU setting experience Noninvasive ventilation in patients with COVID-19-related acute hypoxemic respiratory failure: a retrospective cohort study Invasive mechanical ventilation in COVID-19 patient management: the experience with 469 patients in Wuhan Effectiveness of noninvasive ventilation in COVID-19 related-acute respiratory distress syndrome Outcome of noninvasive ventilation in COVID-19 critically ill patients: a retrospective observational study Clinical course and outcomes of critically ill patients with SARS-CoV-2 pneumonia in Wuhan, China: a single-centered, retrospective, observational study Feasibility and clinical impact of out-of-ICU noninvasive respiratory support in patients with COVID-19-related pneumonia Relatively large observational study reporting the failure rate and the mortality rate of patients treated with noninvasive respiratory support outside the ICU during the pandemic Nation-wide observational study reporting the outcomes of 10021 patientes with COVID-19 Noninvasive ventilatory support of patients with COVID-19 outside the intensive care units Effect of helmet noninvasive ventilation vs high-flow nasal oxygen on days free of respiratory support in patients with COVID-19 and moderate to severe hypoxemic respiratory failure: The HENIVOT Randomized Clinical Trial The first randomized controlled trial comparing Helmet NIV and HFNO in patients with COVID-19 hypoxemic respiratory failure. Despite the negative primary outcome (no difference in respiratory support free days) there the Helmet NIV significantly reduced the rate of endotracheal intubation Treatment of acute hypoxemic nonhypercapnic respiratory insufficiency with continuous positive airway pressure delivered by a face mask: a randomized controlled trial Helmet CPAP vs. oxygen therapy in severe hypoxemic respiratory failure due to pneumonia Helmet continuous positive airway pressure vs oxygen therapy to improve oxygenation in community-acquired pneumonia: a randomized, controlled trial Outcomes of COVID-19 patients treated with continuous positive airway pressure outside the intensive care unit This relatively big retrospective observational study shows that delayed intubation in patients treated with CPAP might increase mortality Noninvasive ventilation for COVID-19-associated acute hypoxaemic respiratory failure: experience from a single centre Clinical characteristics and respiratory support of 310 COVID-19 patients, diagnosed at the emergency room: a single-center retrospective study Helmet CPAP to treat hypoxic pneumonia outside the ICU: an observational study during the COVID-19 outbreak Improved survival following ward-based noninvasive pressure support for severe hypoxia in a cohort of frail patients with COVID-19: retrospective analysis from a UK teaching hospital Discriminating between CPAP success and failure in COVID-19 patients with severe respiratory failure Predictors of intubation in COVID-19 patients treated with out-of-ICU continuous positive airway pressure Helmet CPAP treatment in patients with COVID-19 pneumonia: a multicentre cohort study Continuous Positive Airway Pressure (CPAP) face-mask ventilation is an easy and cheap option to manage a massive influx of patients presenting acute respiratory failure during the SARS-CoV-2 outbreak: A retrospective cohort study Continuous positive airway pressure for respiratory support during COVID-19 pandemic: a frugal approach from bench to bedside COVID-19 and acute respiratory failure treated with CPAP Is continuous positive airway pressure (CPAP) a new standard of care for type 1 respiratory failure in COVID-19 patients? A retrospective observational study of a dedicated COVID-19 CPAP service Continuous positive airway pressure to avoid intubation in SARS-CoV-2 pneumonia: a two-period retrospective case-control study Early clinical experience in using helmet continuous positive airway pressure and high-flow nasal cannula in overweight and obese patients with acute hypoxemic respiratory failure from coronavirus disease 2019 Predictors of CPAP outcome in hospitalized COVID-19 patients Continuous positive airway pressure in COVID-19 patients with moderate-Tosevere respiratory failure Diaphragm thickening fraction predicts noninvasive ventilation outcome: a preliminary physiological study Noninvasive CPAP in mild and moderate ARDS secondary to SARS-CoV-2 Positive end-expiratory pressure, pleural pressure, and regional compliance during pronation: an experimental study Physiological study unreveling the mechanism of lung protection during pronation. 93. Gué rin C Prone position reduces spontaneous inspiratory effort in patients with acute respiratory distress syndrome: a bicenter study Predictive factors for success of awake proning in hypoxemic respiratory failure secondary to COVID-19: a retrospective cohort study Feasibility and physiological effects of prone positioning in nonintubated patients with acute respiratory failure due to COVID-19 (PRON-COVID): a prospective cohort study Use of prone positioning in nonintubated patients with COVID-19 and hypoxemic acute respiratory failure Awake pronation with helmet continuous positive airway pressure for COVID-19 acute respiratory distress syndrome patients outside the ICU: a case series Prone and lateral positioning in spontaneously breathing patients With COVID-19 pneumonia undergoing noninvasive helmet CPAP treatment Early conscious prone positioning in patients with COVID-19 receiving continuous positive airway pressure: a retrospective analysis Lung ultrasound can predict response to the prone position in awake nonintubated patients with COVID-19 associated acute respiratory distress syndrome Prone positioning in patients treated with noninvasive ventilation for COVID-19 pneumonia in an Italian emergency department Conscious prone positioning during noninvasive ventilation in COVID-19 patients: experience from a single centre Early self-proning in awake, nonintubated patients in the emergency department: a single ED's experience during the COVID-19 pandemic Prone positioning of nonintubated patients with COVID-19 Prone positioning combined with highflow nasal or conventional oxygen therapy in severe Covid-19 patients Effectiveness of prone position in spontaneously breathing patients with COVID-19: A prospective cohort study Awake prone positioning does not reduce the risk of intubation in COVID-19 treated with high-flow nasal oxygen therapy: a multicenter, adjusted cohort study Early application of prone position for management of Covid-19 patients Successful awake proning is associated with improved clinical outcomes in patients with COVID-19: single-centre highdependency unit experience The POSITIONED Study: prone positioning in nonventilated coronavirus disease 2019 patients-a retrospective analysis Prone positioning in management of COVID-19 hospitalized patients Awake prone positioning for nonintubated oxygen dependent COVID-19 pneumonia patients Awake prone positioning in COVID-19 hypoxemic respiratory failure: exploratory findings in a singlecenter retrospective cohort study Effect of prone positioning on the respiratory support of nonintubated patients with COVID-19 and acute hypoxemic respiratory failure: a retrospective matching cohort study Prone positioning in nonintubated patients with COVID-19 outside of the intensive care unit: more evidence needed Respiratory parameters in patients with COVID-19 after using noninvasive ventilation in the prone position outside the intensive care unit Effectiveness of dexmedetomidine combined with high flow nasal oxygen and long periods of awake prone positioning in moderate or severe COVID-19 pneumonia Prone positioning in awake, nonintubated patients with COVID-19 hypoxemic respiratory failure Early awake proning in critical and severe COVID-19 patients undergoing noninvasive respiratory support: a retrospective multicenter cohort study Prone positioning in high-flow nasal cannula for COVID-19 patients with severe hypoxemia: a pilot study Early awake prone position combined with high-flow nasal oxygen therapy in severe COVID-19: a case series Efficacy of early prone position for COVID-19 patients with severe hypoxia: a single-center prospective cohort study Awake prone positioning and oxygen therapy in patients with COVID-19: The APRONOX study In this relatively big observational study the use of awake prone position reduced intubation and mortality rate at univariate, at multivariate and after propensity score matched analysis Standard care versus awake prone position in adult nonintubated patients with acute hypoxemic respiratory failure secondary to COVID-19 Infection-a multicenter feasibility randomized controlled trial Patient-directed prone positioning in awake patients with COVID-19 requiring hospitalization (PAPR) Financial support and sponsorship None.